The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer

Inclusion Criteria: * Patients diagnosed with prostate cancer that elect to undergo primary cryotherapy of the prostate * Patients who are diagnosed with clinical stage T1a -T2c prostate cancer * Gleason score sum of less than or equal to 7 * Prostate-specific antigen (PSA) \< 20 ng/dl * Patient will read, understand and sign the informed consent and Health Insurance Portability and Accountability Act (HIPAA) agreement * Patients must have a life expectancy of at least one year Exclusion Criteria: * Known hypersensitivity to granulocyte macrophage colony stimulating factor (GM-CSF) or yeast * Anticipated blood donation within the next 90 days * Magnetic resonance imaging (MRI), computed tomography (CT) and bone scan evidence of metastatic prostate cancer regardless the PSA level; (the indication for which is clinically driven and at the discretion of the treating physician) * Any history of current or within the past 48 hours of acute or chronic bacterial, fungal or viral infectious disease * Documented excessive leukemic myeloid blasts in the bone marrow or peripheral blood (\>= 10%) in the past 6 months * Previous organ transplant * Immunosuppression including primary, secondary, iatrogenic and idiopathic * Other serious diseases (hematological, hepatic, renal, respiratory, central nervous system, autoimmune or psychiatric) * Enrollment in other studies for any disease in the past 30 days * Diagnosis of cancer that in not considered cured, except basal cell carcinoma (BCC) of skin * Prior transurethral resection of the prostate with a large tissue defect (at the discretion of the investigator) * History of abdominoperineal resection for rectal cancer, rectal stenosis, or other major rectal pathology * Patient currently receiving lithium, steroid, chemotherapy or radiotherapy treatment * Patients with a Hemoglobin of less than 12%